<DOC>
	<DOC>NCT02479217</DOC>
	<brief_summary>The primary objective of this study is to observe safety and tolerability of Xeloda as used in medical practice, alone and in combination with docetaxel.</brief_summary>
	<brief_title>Safety of Xeloda in Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Metastatic Breast Cancer: women &gt;=18 years of age Patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracyclinecontaining chemotherapy regimen or for whom further anthracycline therapy is not indicated. Female patients with histopathologically proven metastatic breast cancer Adequate bone marrow, liver, renal and cardiac functions Colon Cancer: Patients &gt;18 years of age Patients with histologicaly confirmed colon cancer Patients with potential curative tumor resection within 8 weeks before enrolment in the study Patients previously not treated with chemiotherapy Metastatic Breast Cancer: Patients previously treated with docetaxel (Taxotere) or capecitabine (Xeloda) Patients with contraindications for any of study drugs as listed in approved SmPC Colon Cancer: Patients previously treated with chemiotherapy Patients with contraindications for study drug as listed in approved SmPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>